Natera, Inc. (NTRA) research: valuation against peers, fundamentals over time, risk and news coverage
NTRA
Natera, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- SPECIAL REPORTBEARISHInsider Selling Wave Broadens Across Mid-Cap America as Executives Cash Into Strength
A dense cluster of Form 4 disclosures spanning healthcare services, consumer retail, diagnostics, consumer durables and software points to coordinated executive de-risking into post-earnings rallies. Encompass Health saw three separate insiders sell after a rate increase, with the CFO cutting his direct common position 27% and CEO Mark Tarr trimming while retaining roughly 268,000 shares worth $33.7 million.
- MARKET REPORTBEARISHInsider Selling Broadens Across Media, Diagnostics and Corrections Names
A wide cross-section of insiders reduced holdings in the latest filing batch, led by Warner Bros. Discovery CEO David Zaslav's $27.1 million sale, alongside disposals at Natera, Morningstar, CoreCivic, California Water Service and AeroVironment.
- SPECIAL REPORTNEUTRALQ2 Earnings Wave Splits Market: Medtech and Fintech Beat as Consumer Names Retrench
Natera oncology volumes rose 57.2%, iRhythm revenue climbed 20% with raised guidance, ICU Medical posted record Infusion Systems revenue on 12% organic growth, and Nu Holdings cleared $1B in quarterly profit. Offsetting that, Post's pet food volumes fell 7.8%, i3 Verticals cut guidance, and Dragonfly Energy is pivoting away from a soft RV end market.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.